NEW YORK (GenomeWeb News) – Synthetic Genomics and New England Biolabs announced on Tuesday a non-exclusive licensing agreement for the commercialization of the Gibson Assembly Master Mix.
The deal calls for NEB to commercialize the product, which is based on the Gibson Assembly method, developed by Daniel Gibson and colleagues at the J. Craig Venter Institute as part of a program sponsored by Synthetic Genomics.
Gibson Assembly is a one-step isothermal approach for multiple DNA fragment assembly, and the Gibson Master Mix, which includes protocols for primer design, can be used to assemble multiple DNA fragments, including linearized vector and insert. NEB's Gibson Assembly Master Mix can be used to assemble such synthetic nucleic acids into larger genetic constructs, Synthetic Genomics said.
Craig Venter, founder and CEO of Synthetic Genomics, in a statement called the Gibson Assembly method "a powerful tool that we believe will enable synthetic biology researchers to make rapid advances leading to new discoveries and products."
Terms of the deal were not disclosed.
Earlier this month, Synthetic Genomics and Integrated DNA Technologies said they would manufacture, market, and commercialize small synthetic gene products.